3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia
2
Depression
2
Tuberous Sclerosis
1
Tourette Syndrome
1
Tic Disorders
1
Preleukemia
1
Neurodevelopmental Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Hot Flashes
1
Hematologic Diseases
1
Glioblastoma
1
Fragile X Syndrome
1
DiGeorge Syndrome
1
Cytopenia
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Autistic Disorder
1
Autism Spectrum Disorder
1
Attention Deficit Disorder with Hyperactivity
1
Anxiety Disorders
1
Anemia
1
22q11 Deletion Syndrome
1
Interventions
fludarabine
12
Cyclophosphamide
11
Busulfan
8
Mycophenolic Acid
6
Dexamethasone
6
fludarabine phosphate
5
Whole-Body Irradiation
5
Tacrolimus
5
Melphalan
5
Lenalidomide
5
Granulocyte Colony-Stimulating Factor
4
isatuximab
3
Thiotepa
3
Sirolimus
3
Rituximab
3
Methotrexate
3
Cyclosporine
3
Blood Specimen Collection
3
Alemtuzumab
3
pomalidomide
2
pembrolizumab
2
daratumumab
2
Vorinostat
2
Stem Cell Transplantation
2
Platelet Transfusion
2
Ondansetron
2
Interviews as Topic
2
Filgrastim
2
Exercise
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hematologic Diseases
×
Sertraline
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled